Incidence of Bloodstream Infections Due to Candida Species and In Vitro Susceptibilities of Isolates Collected from 1998 to 2000 in a Population-Based Active Surveillance Program
Centers for Disease Control and Prevention · National Center for Infectious Diseases · +2 more institutions
Abstract
To determine the incidence of Candida bloodstream infections (BSI) and antifungal drug resistance, population-based active laboratory surveillance was conducted from October 1998 through September 2000 in two areas of the United States (Baltimore, Md., and the state of Connecticut; combined population, 4.7 million). A total of 1,143 cases were detected, for an average adjusted annual incidence of 10 per 100,000 population or 1.5 per 10,000 hospital days. In 28% of patients, Candida BSI developed prior to or on the day of admission; only 36% of patients were in an intensive care unit at the time of diagnosis. No fewer than 78% of patients had a central catheter in place at the time of diagnosis, and 50% had…
Citation impact
- FWCI
- 24.44
- Percentile
- 100%
- References
- 56
Authors
16- RHRana HajjehCorresponding
Centers for Disease Control and Prevention, National Center for Infectious Diseases
- ANAndré N. Sofair
Yale University
- LHLee H. Harrison
Johns Hopkins University
- GMG. Marshall Lyon
Centers for Disease Control and Prevention, National Center for Infectious Diseases
- BABeth A. Arthington‐Skaggs
Centers for Disease Control and Prevention, National Center for Infectious Diseases
Topics & keywords
- Fluconazole
- Microbiology
- Candida tropicalis
- Candida glabrata
- Corpus albicans
- Population
- Fungemia
- Amphotericin B
- Good health and well-being